Private company

RVL Pharmaceuticals plc

Pharmaceutical preparations company that raised $5 million in 2023 (SEC Form D)1

In its 2023 annual report the company says: “We are a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. We acquired the worldwide rights to RVL-1201 in 2017 in exchange for an upfront cash payment plus the obligation to make additional payments consisting of future earn-out payments to the sellers of RevitaLid based on net sales of Upneeq.”48 It is headquartered in Bridgewater, New Jersey.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersBridgewater, New Jersey1
  • Incorporated inIreland2
  • Business address400 Crossing Boulevard, Bridgewater, Nj 088072
  • Filer category, Emerging growth company2
  • Legal formOther

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

81.0%Gross margin3
-118.6%Operating margin3
-104.0%Net margin3
184.1%Revenue growth, 20223
-101.2%Return on equity3
1.47×Debt to equity3
-$38.6MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue10¢$9.5M
  • Research and development4¢$4.0M
  • Selling, general and admin83¢$82.0M
  • Interest3¢$3.1M
  • Income tax0¢$20.0K

Out of $49.7M in revenue.3 The company lost money this year.

Financial statements

Revenue45673$49.7M in 2022−80% since 2017
0$100.0M$200.0M$300.0M2017: $245.7M$245.7M20172018: $263.7M$263.7M2018+7%2019: $240.0M$240.0M2019−9%2020: $27.8M$27.8M2020−88%2021: $17.5M$17.5M2021−37%2022: $49.7M$49.7M2022+184%
Gross profit45673$40.3M in 2022−67% since 2017
0$50.0M$100.0M$150.0M2017: $120.6M$120.6M20172018: $123.6M$123.6M2018+3%2019: $128.4M$128.4M2019+4%2020: $24.5M$24.5M2020−81%2021: $13.9M$13.9M2021−43%2022: $40.3M$40.3M2022+190%
Operating income45673-$59.0M in 2022+13% since 2017
-$300.0M-$200.0M-$100.0M02017: -$52.1M-$52.1M20172018: -$98.5M-$98.5M2018+89%2019: -$280.7M-$280.7M2019+185%2020: -$90.7M-$90.7M2020−68%2021: -$82.8M-$82.8M2021−9%2022: -$59.0M-$59.0M2022−29%
Net income45673-$51.7M in 2022+26% since 2017
-$300.0M-$200.0M-$100.0M02017: -$41.1M-$41.1M20172018: -$109.7M-$109.7M2018+167%2019: -$270.9M-$270.9M2019+147%2020: -$79.6M-$79.6M2020−71%2021: -$64.9M-$64.9M2021−18%2022: -$51.7M-$51.7M2022−20%
Fiscal year2016201720182019202020212022
Revenue$245.7M4$263.7M5$240.0M6$27.8M7$17.5M3$49.7M3
Cost of revenue$125.2M4$140.1M5$111.6M6$3.3M7$3.6M3$9.5M3
Gross profit$120.6M4$123.6M5$128.4M6$24.5M7$13.9M3$40.3M3
Research and development$42.7M4$43.7M5$32.3M6$13.4M7$6.9M3$4.0M3
Selling, general and admin$57.0M4$74.2M5$93.0M6$72.8M7$87.5M3$82.0M3
Operating expenses$102.3M3$99.3M3
Operating income-$52.1M4-$98.5M5-$280.7M6-$90.7M7-$82.8M3-$59.0M3
Interest$29.1M4$20.8M5$18.2M6$4.1M7$3.0M3$3.1M3
Income before tax-$82.5M3-$51.7M3
Income tax-$44.5M4-$9.0M5-$27.1M6$5.8M7-$315.0K3$20.0K3
Net income-$41.1M4-$109.7M5-$270.9M6-$79.6M7-$64.9M3-$51.7M3
Earnings per share-$1.317-$0.963-$0.583
Earnings per share (diluted)-$1.317-$0.963-$0.583
Shares (weighted, basic)67.4M shares389.8M shares3
Shares (weighted, diluted)67.4M shares389.8M shares3

Compare RVL Pharmaceuticals plc with another company

Corporate structure

RVL Pharmaceuticals plc sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of RVL Pharmaceuticals plc

  • Athyrium Opportunities IV Acquisition 2 LP Filed SC 13D/A on RVL Pharmaceuticals plc, latest Nov 28, 2023 (5 filings since Oct 22, 2021)
  • Altchem Ltd Filed SC 13D/A on RVL Pharmaceuticals plc, latest Nov 1, 2023 (2 filings since Nov 3, 2021)
  • Avista Healthcare Partners GP, Ltd. Filed SC 13D/A on RVL Pharmaceuticals plc, latest Aug 17, 2023 (2 filings since Jan 30, 2023)
  • Avista Capital Partners III GP, L.P. Filed SC 13D/A on RVL Pharmaceuticals plc, latest Aug 9, 2022 (2 filings since Oct 14, 2021)
  • RVL Pharmaceuticals plc Bridgewater, New Jersey

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What RVL Pharmaceuticals plc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Construction in progress$700.0K3 Dec 31, 2022$72.0K3 Dec 31, 2021+872.2%
Finance-lease assets$28.0K3 Dec 31, 2022$5.0K3 Dec 31, 2021+460.0%
Operating-lease assets (leased space)$512.0K3 Dec 31, 2022$1.4M3 Dec 31, 2021−62.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$55.8M3 Dec 31, 2022$55.8M3 Dec 31, 20210%
Intangible assets, net (excluding goodwill)$13.9M3 Dec 31, 2022$27.2M3 Dec 31, 2021−48.9%

Inventory

ItemLatestA year beforeChange
Inventory, total$784.0K3 Dec 31, 2022$838.0K3 Dec 31, 2021−6.4%
Finished goods$838.0K7 Dec 31, 2021$1.6M7 Dec 31, 2020−47.4%

Leadership

Who has led RVL Pharmaceuticals plc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Brian A. Markison2018–2022

Chief financial officer

  1. Andrew J. Einhorn2018–2022

Chief operating officer

  1. James Schaub2018–2023
20202025
Board members and other officers (11)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorJOAQUIN BENES named Aug 31, 202323

Former names

  • Osmotica Pharmaceuticals plcJun 8, 2018 to Jan 18, 20222
  • Osmotica Pharmaceuticals LtdMay 9, 2018 to Aug 22, 20182

Timeline

  1. Feb 13, 20248-K Other events24
  2. Jan 17, 20248-K Other events25
  3. Dec 20, 20238-K Shareholder vote26
  4. Nov 27, 20238-K Bankruptcy or receivership; Completed an acquisition or sale; Other events27
  5. Nov 6, 20238-K Regulation FD disclosure28
  6. Oct 20, 20238-K Entered a material agreement; Bankruptcy or receivership; New debt or obligation29
  7. Oct 13, 20238-K Ended a material agreement; Bankruptcy or receivership; New debt or obligation30
  8. Sep 29, 20238-K Other events31
  9. Sep 22, 20238-K Executive or director change32
  10. Sep 5, 20238-K Other events33
  11. Aug 25, 20238-K Regulation FD disclosure34
  12. Aug 18, 20238-K Entered a material agreement; Unregistered sale of shares; Other events35
  13. Oct 18, 2018New chief executive Brian A. Markison becomes CEO10

Calendar

When it reported results

  1. Aug 14, 2023Reported quarterly or annual results36
  2. May 11, 2023Reported quarterly or annual results37
  3. Mar 20, 2023Reported quarterly or annual results38
  4. Jan 9, 2023Reported quarterly or annual results39
  5. Nov 10, 2022Reported quarterly or annual results40
  6. Oct 18, 2022Reported quarterly or annual results41
  7. Aug 11, 2022Reported quarterly or annual results42
  8. Jul 7, 2022Reported quarterly or annual results43

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

142 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 38 major events, 38 insider forms, 11 large holders, 1 private raises, 46 other. The latest 20:

  1. Feb 13, 20248-K EDGAR
  2. Jan 17, 20248-K EDGAR
  3. Dec 20, 20238-K EDGAR
  4. Nov 28, 2023SC 13D/A EDGAR
  5. Nov 27, 20238-K EDGAR
  6. Nov 16, 2023DEF 14A EDGAR
  7. Nov 6, 2023PRE 14A EDGAR
  8. Nov 6, 20238-K EDGAR
  9. Nov 1, 2023SC 13D/A SC 13D/A (AMENDMENT NO. 2) EDGAR
  10. Oct 23, 20234 PRIMARY DOCUMENT EDGAR
  11. Oct 23, 20234 PRIMARY DOCUMENT EDGAR
  12. Oct 20, 20234 PRIMARY DOCUMENT EDGAR
  13. Oct 20, 20234 PRIMARY DOCUMENT EDGAR
  14. Oct 20, 20238-K EDGAR
  15. Oct 18, 2023144 EDGAR
  16. Oct 13, 2023SC 13D/A EDGAR
  17. Oct 13, 20238-K EDGAR
  18. Sep 29, 20238-K EDGAR
  19. Sep 25, 2023144 EDGAR
  20. Sep 22, 20238-K EDGAR

The 142 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

12 open-market trades by officers, directors and large owners since October 2021: 6 buys and 6 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 20, 2023Harsaul Foundation10% ownerSale4,758,899$0.03$142.8KForm 4
Oct 20, 2023Altchem Ltd10% ownerSale4,758,899$0.03$142.8KForm 4
Oct 19, 2023Harsaul Foundation10% ownerSale9,363,760$0.05$468.2KForm 4
Oct 19, 2023Altchem Ltd10% ownerSale9,363,760$0.05$468.2KForm 4
Oct 18, 2023Harsaul Foundation10% ownerSale3,421,537$0.06$205.3KForm 4
Oct 18, 2023Altchem Ltd10% ownerSale3,421,537$0.06$205.3KForm 4
Aug 8, 2022Schaub JamesEVP and COOBuy150,000$1.55$232.5KForm 4
Aug 8, 2022MARKISON BRIAN AChief Executive OfficerBuy850,000$1.55$1.3MForm 4
Aug 8, 2022Burgstahler David FDirectorBuy8,000,000$1.55$12.4MForm 4
Aug 8, 2022Venkataraman SriramDirectorBuy8,000,000$1.55$12.4MForm 4
Aug 8, 2022Orbit Co-Invest III LLC10% ownerBuy8,000,000$1.55$12.4MForm 4
Dec 16, 2021Schaub JamesEVP and COOBuy93,800$1.07$100.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Aug 18, 2023Raised $5 million in a private offering of securities Form D: 1 investor so far Form D

SEC filer profile

How RVL Pharmaceuticals plc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARRVL Pharmaceuticals plc1
  • CIK0001739426
  • Filer status<br>emerging growth company1
  • Incorporated inIreland1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address400 Crossing Boulevard, Bridgewater, NJ 088071
  • Phone90880913001
  • Shares outstanding99,535,197 as of Aug 11, 20239
  • Public float$44.9M as of Jun 30, 20223
  • On EDGAR sinceMay 9, 20181
  • Filings323 in all: 4 (80), 8-K (79), CORRESP (19), 3 (18), 10-Q (15), UPLOAD (13), DEF 14A (9), SC 13D/A (9)1
    All 35 form types

    144 (7), EFFECT (7), PRE 14A (7), 424B5 (6), DEFA14A (6), 10-K (5), S-3 (5), 3/A (4), SC 13G (4), DRS/A (3), S-1/A (3), SC 13D (3), 424B4 (2), CT ORDER (2), DRSLTR (2), S-1 (2), S-8 (2), SC 13G/A (2), 10-K/A (1), 25-NSE (1), 424B3 (1), 8-A12B (1), ARS (1), CERT (1), D (1), DRS (1), FWP (1)

  • Latest filingsAnnual report (10-K) Mar 20, 2023
    Quarterly report (10-Q) Aug 14, 2023
    Proxy statement (DEF 14A) Nov 16, 2023
    Latest 8-K (8-K) Feb 13, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
    SEC EDGAROther events
  25. 25
    SEC EDGAROther events
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
    SEC EDGAROther events
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48